Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Gill, Mundin"'
Autor:
Ferran Gonzalez Hernandez, Quang Nguyen, Victoria C. Smith, José Antonio Cordero, Maria Rosa Ballester, Màrius Duran, Albert Solé, Palang Chotsiri, Thanaporn Wattanakul, Gill Mundin, Watjana Lilaonitkul, Joseph F. Standing, Frank Kloprogge
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract The development of accurate predictions for a new drug’s absorption, distribution, metabolism, and excretion profiles in the early stages of drug development is crucial due to high candidate failure rates. The absence of comprehensive, sta
Externí odkaz:
https://doaj.org/article/0151c6cf91724371bab3aea59839f651
Publikováno v:
Journal of Aerosol Medicine and Pulmonary Drug Delivery. 36:65-75
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a6dc34ff6154c10907d232960f8ca16
https://doi.org/10.1089/jamp.2022.0064
https://doi.org/10.1089/jamp.2022.0064
Autor:
Alexander Oksche, Kevin J. Smith, Gaia Rizzo, Eugenii A. Rabiner, Helen Dooner, Yvonne Lewis, Gill Mundin, Carla Bennett
Publikováno v:
British journal of clinical pharmacologyREFERENCES. 88(4)
BACKGROUND AND PURPOSE Preclinical studies of MR309, a selective sigma1 receptor (σ1R) antagonist, support a potential role in treating neuropathic pain. We report two studies that provide insight into the pharmacokinetics (PK) and brain σ1R bindin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2ac018600c5631c13d2c48676ace214
https://pubmed.ncbi.nlm.nih.gov/34156715
https://pubmed.ncbi.nlm.nih.gov/34156715
Publikováno v:
European Journal of Pharmaceutical Sciences. 122:125-133
Purpose A novel sublingual buprenorphine/naloxone rapidly-dissolving tablet (BNX-RDT) for opioid substitution therapy has been developed for improved bioavailability, rapid disintegration and improved taste masking. We compared the bioavailability an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bd95317516ea070ae31880feabaa043
https://doi.org/10.1016/j.ejps.2018.06.024
https://doi.org/10.1016/j.ejps.2018.06.024
Autor:
Gill Mundin, Kevin Smith, John Strang, Rebecca McDonald, Ulrike Lorch, Björn Bosse, Jo Woodward, Helen Dooner
Publikováno v:
Addiction. 113:484-493
Background and Aims Take-home naloxone can prevent death from heroin/opioid overdose, but pre-provision is difficult because naloxone is usually given by injection. Non-injectable alternatives, including naloxone nasal sprays, are currently being dev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df03583afab3712b24ab895eb1e266ae
https://doi.org/10.1111/add.14033
https://doi.org/10.1111/add.14033
Publikováno v:
Addiction. 112:1647-1652
Background and Aims Lack of non-injectable naloxone formulations has impeded widespread take-home provision for the prevention of heroin/opioid overdose deaths. For non-injectable formulations that are finally being investigated, rapid onset of actio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6d4afe5bb600befe9b5d52475823288
https://doi.org/10.1111/add.13849
https://doi.org/10.1111/add.13849
Publikováno v:
Journal of Pain and Symptom Management. 51:538-545
Context Salivary gland hypofunction may affect the absorption of drugs through the oral mucosa, which in turn may affect their clinical efficacy (e.g., onset of action). Objectives The aim of this study was to assess the pharmacokinetics of a subling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d23b2e53745f0e01d71d9d83bc010f1
https://doi.org/10.1016/j.jpainsymman.2015.11.018
https://doi.org/10.1016/j.jpainsymman.2015.11.018
Autor:
Carla Bennett, Marisol Escriche, Sabine Mersmann, Kevin John Smith, Gregorio Encina, Mercedes Encabo, Helen Dooner, Gill Mundin, Ulrike Lorch
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Background and Objectives Co-Crystal of Tramadol-Celecoxib (CTC) is a first-in-class active pharmaceutical ingredient (API–API) co-crystal of rac-tramadol.HCl and celecoxib in a 1:1 molecular ratio (100 mg CTC: 44 mg rac-tramadol.HCl and 56 mg cele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bac6a4c58dcaa816b68288e235e3bdc3
https://pubmed.ncbi.nlm.nih.gov/29956215
https://pubmed.ncbi.nlm.nih.gov/29956215
Publikováno v:
Airway Pharmacology and Treatment.
Background: Two-stage (S1, S2) adaptive design study to compare systemic BA and PD of FP and FORM via the BTI (Flutiform® K-haler®), and pMDI with (+S) or without a spacer (EudraCT: 2013-000045-39). Methods: Single-dose, randomised, open-label cros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30d8ba1715399fc51602a0566ba1970c
https://doi.org/10.1183/1393003.congress-2017.pa3950
https://doi.org/10.1183/1393003.congress-2017.pa3950
Publikováno v:
Airway Pharmacology and Treatment.
Background: This study aimed to show that pulmonary BA of FP and FORM via the BTI (Flutiform® K‑haler®) was no less than via pMDI without a spacer, to establish a bridge from the efficacy of the pMDI to the BTI (EudraCT: 2012-003728-19). Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a55b6cd8457534b7fe06cc07ba6c2f6
https://doi.org/10.1183/1393003.congress-2017.pa523
https://doi.org/10.1183/1393003.congress-2017.pa523